Markers of Favorable Response to Complement Inhibitors Therapy

Inclusion Criteria

• •Age ≥18 years;
• •Diagnosis of generalized anti-AChR positive Myasthenia Gravis;
• •Need for therapy with complement inhibitor drugs according to the therapeutic indications approved by AIFA (16);
• •Ability to perform follow-up at the reference center;
• •Signed informed consent to the study.